Metformin attenuates cuprizone-induced mitochondrial dysfunction and senescence-associated changes in primary...

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Mitochondrial dysfunction and cellular senescence are hallmarks of brain aging and neurodegenerative diseases.
• Cuprizone (CPZ) is a neurotoxin that induces mitochondrial damage, oxidative stress, and iron accumulation.

Purpose of the Study:

• To investigate the protective effects of metformin (MFN), an AMPK activator, against CPZ-induced mitochondrial and senescence-like changes in neuronal cells.
• To explore MFN's potential therapeutic role in mitigating neurodegeneration.

Main Methods:

• Primary neuronal cultures were treated with CPZ to induce toxicity.
• Confocal and transmission electron microscopy were used to assess mitochondrial morphology and damage.
• Reactive oxygen species (ROS), iron accumulation, lipofuscin, and lipid radicals were quantified.
• Gene expression analysis was performed to identify changes in mitochondria-related pathways.

Main Results:

• CPZ treatment caused mitochondrial enlargement, increased ROS production, iron accumulation, and lipofuscin formation.
• MFN treatment significantly reduced abnormal mitochondrial morphology, mitoROS levels, and iron accumulation.
• MFN prevented increases in lipofuscin and lipid radicals.
• Gene expression analysis revealed MFN's impact on pathways related to lipid peroxidation, oxidative stress, and senescence.

Conclusions:

• Metformin effectively mitigates CPZ-induced mitochondrial dysfunction and cellular senescence.
• MFN demonstrates therapeutic potential for age-related neurodegenerative conditions characterized by mitochondrial damage and oxidative stress.